金复康口服液联合培美曲塞对非小细胞肺癌患者免疫功能、肿瘤标志物及血清VEGF、MMP-9水平的影响  

Effect of Jinfukang Oral Liquid Combined with Pemetrexed on Immune Function, Tumor Markers and Serum VEGF, MMP-9 Levels in Patients with Non-small Cell Lung Cancer

作　　者：肖凌[1] 李和根[1] 徐蔚杰[1] 周蕾[1] 姚逸临[1] 周之毅[1] 朱丽华[1] 慕晓艳[1] XIAO Ling;LI He-gen;XU Wei-jie;ZHOU Lei;YAO Yi-lin;ZHOU Zhi-yi;ZHU Li-hua;MU Xiao-yan(Department of Oncology,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai,200032,China)

机构地区：[1]上海中医药大学附属龙华医院肿瘤科,上海200032

出　　处：《现代生物医学进展》2021年第13期2503-2507,共5页Progress in Modern Biomedicine

基　　金：国家十三五"重大新药创制"科技重大专项(2017ZX09304001);上海市进一步加快中医药事业发展三年行动计划[ZY(2018-2020)];上海市重中之重临床医学中心和重点学科建设项目(2017ZZ01010)。

摘　　要：目的:观察金复康口服液联合培美曲塞对非小细胞肺癌(NSCLC)患者免疫功能、肿瘤标志物及血清血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)水平的影响。方法:研究所涉及的60例NSCLC患者均为2017年8月至2020年8月期间我院收治的患者。根据随机数字表法将患者分为对照组和观察组,分别为30例。其中对照组给予培美曲塞联合顺铂化疗,观察组在对照组的基础上联合金复康口服液治疗,均以21 d为1个疗程,治疗4个疗程。对比两组治疗4个疗程后的疗效,对比两组治疗前、治疗4个疗程后的免疫功能、肿瘤标志物[细胞角质素片段抗原21-1 (CYFRA21-1)、糖类抗原125(CA125)、癌胚抗原(CEA)]及血清VEGF、MMP-9水平,对比两组毒副反应。结果:观察组的疾病控制率高于对照组(P<0.05)。治疗4个疗程后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)下降,但观察组高于对照组(P<0.05)。治疗4个疗程后,两组CA125、CYFRA21-1、CEA水平下降,且观察组低于对照组(P<0.05)。治疗4个疗程后,两组血清MMP-9、VEGF水平下降,且观察组低于对照组(P<0.05)。两组的毒副反应总发生率对比无差异(P>0.05)。结论:金复康口服液联合培美曲塞治疗NSCLC患者,可控制病灶,降低血清MMP-9、VEGF水平,减轻免疫抑制,安全有效。Objective: To observe the effect of Jinfukang oral liquid combined with pemetrexed on immune function, tumor markers and serum vascular endothelial growth factor(VEGF) and matrix metalloproteinase-9(MMP-9) levels in patients with non-small cell lung cancer(NSCLC). Methods: The 60 patients with NSCLC involved in the study were all patients admitted to our hospital from August 2017 to August 2020. According to the random number table method, the patients were divided into control group and observation group, 30 cases in each group. The control group was treated with pemetrexed combined with cisplatin chemotherapy, and the observation group was treated with Jinfukang oral liquid on the basis of the control group, with 21 days as a course of treatment, and 4 courses of treatment. The efficacy of the two groups at 4 courses after treatment was compared. The immune function, tumor markers [cytokeratin fragment antigen 21-1(CYFRA21-1), carbohydrate antigen 125(CA125), carcinoembryonic antigen(CEA)], serum VEGF, MMP-9 levels before and 4 courses after treatment were compared between the two groups, and the toxic and side effects were compared between the two groups. Results: The disease control rate of the observation group were higher than those of the control group(P<0.05). 4 courses after treatment, CD3^(+), CD4^(+), CD4^(+)/CD8^(+)in the two groups decreased, but the observation group was higher than the control group(P<0.05).4 courses after treatment, CA125, CYFRA21-1 and CEA levels decreased in the two groups, and the observation group was lower than the control group(P<0.05). 4 courses after treatment, MMP-9 and VEGF levels decreased in the two groups, and the observation group was lower than the control group(P<0.05). There was no difference in the total incidence rate of toxic and side reactions between the two groups(P>0.05). Conclusion: Jinfukang oral liquid combined with pemetrexed in the treatment of patients with NSCLC can control the focus, reduce serum MMP-9 and VEGF levels, reduce immunosuppression, and

关 键 词：金复康口服液 培美曲塞 非小细胞肺癌 免疫功能 肿瘤标志物 VEGF MMP-9 

分 类 号：R734.2[医药卫生—肿瘤]